This is a preview of subscription content, log in via an institution to check access.
Notes
2019 euros
Reference
Patrizio A, et al. Cost-Effectiveness and Net Monetary Benefit of olaparib Maintenance Therapy Versus No Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-Mutated Ovarian Cancer in the Italian National Health Service. . Clinical Therapeutics : 23 Jun 2020. Available from: URL: http://doi.org/10.1016/j.clinthera.2020.04.015
Rights and permissions
About this article
Cite this article
Olaparib maintenance cost effective for advanced ovarian cancer. PharmacoEcon Outcomes News 857, 23 (2020). https://doi.org/10.1007/s40274-020-6960-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6960-9